Journal profile · Immunology
International Immunopharmacology
ISSN 1567-5769 · eISSN 1878-1705 · Elsevier · NETHERLANDS · Monthly · Founded 2001
International Immunopharmacology: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 5.61; hybrid open access; APC about USD 3,220; median 87 days to acceptance (175 articles, last 24 months); community-reported acceptance: about 81.66%; 1,963 articles in 2025; indexed in SCIE and Scopus; the journal's website says submissions are paused or closed.
The journal's website announces a move to full open access: At Elsevier, we are committed to advancing human progress and making research accessible to everyone. We are pleased to announce that from January 1, 2027, International Immunopharmacology will become a fully open access journal, with all articles freely available to readers worldwide. Source ↗Publisher website ·
The journal's website says submissions are paused or closed: International Immunopharmacology no longer accept manuscripts consisting solely of meta-analyses, bibliometric studies, or statistical analyses of publicly available datasets. Source ↗Publisher website ·
Scope
Aims, scope and focus
International Immunopharmacology is published by Elsevier and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Immune Response and Inflammation, Immune Cell Function and Interaction and Immune cells in cancer, together about 24.4% of its articles. Its main subfields are Immunology. (generated from OpenAlex topic counts and CAS ranking data)
International Immunopharmacology is the primary vehicle for the publication of original research papers pertinent to the overlapping areas of immunology, pharmacology, cytokine biology, immunotherapy, immunopathology and immunotoxicology. Review articles that encompass these subjects are also welcome.International Immunopharmacology does not accept submissions that consist primarily of bioinformatics or computational analyses of public genomic or transcriptomic databases, unless they are supported by experimental studies involving cells, organoids, or experimental animals.International Immunopharmacology no longer accept manuscripts consisting solely of meta-analyses, bibliometric studies, or statistical analyses of publicly available datasets.The subject material appropriate for submission includes: • Clinical studies employing immunotherapy of any type including the use of: bacterial and chemical agents; thymic hormones, interferon, lymphokines, etc., in transplantation and diseases such as cancer, immunodeficiency, chronic infection and allergic, inflammatory or autoimmune disorders. • Studies on the mechanisms of action of these agents for specific parameters of immune competence as well as the overall clinical state. • Pre-clinical animal studies and in vitro studies on mechanisms of action with immunopotentiators, immunomodulators, immunoadjuvants and other pharmacological agents active on cells participating in immune or allergic responses. • Pharmacological compounds, microbial products and toxicological agents that affect the lymphoid system, and their mechanisms of action. • Agents that activate genes or modify transcription and translation within the immune response. • Substances activated, generated, or released through immunologic or related pathways that are pharmacologically active. • Production, function and regulation of cytokines and their receptors. • Classical pharmacological studies on the effects of chemokines and bioactive factors released during immunological reactions. • Studies on the nature and function of drug and hormone receptors on lymphocytes and other cells in the immune system.• Studies of cell-derived or humoral factors that modify the immune system causing cytotoxicity, inducing antibody production and mediating inflammatory responses. • The development of immunologically based assays and their application to disease, including assays for drugs, hormones, cyclic nucleotides, tumor antigens, etc.
From the journal's Aims & Scope
Research area (LetPub): Immunology
Editor-in-chief Jean-Pierre GorvelPublisher website
Editorial board by country: 48 in mainland China (about 55%); most named Mainland China 48, United States 18, India 6, Japan 4, Italy 2 (87 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Immune Response and InflammationImmunology and Microbiology8.9%
- Immune Cell Function and InteractionImmunology and Microbiology8%
- Immune cells in cancerImmunology and Microbiology7.5%
- Inflammasome and immune disordersBiochemistry, Genetics and Molecular Biology7.2%
- Immunotherapy and Immune ResponsesImmunology and Microbiology5.6%
- Neuroinflammation and Neurodegeneration MechanismsNeuroscience5.5%
- Cancer Immunotherapy and BiomarkersMedicine4.9%
- Ferroptosis and cancer prognosisMedicine4.3%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
| Minor | Immunology | Zone 3 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: yesReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Immunology | Zone 2 |
| Minor | Pharmacology & Pharmacy | Zone 2 |
Top journal: yesReview journal: no
Database indexing
SCIEScopusLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor
- 5.61LetPub ·
- Impact factor (publisher)
- 5.6Publisher website ·
- CiteScore 2026-06
- 8.1LetPub ·
- CiteScore (publisher)
- 8.1Publisher website ·
- SJR 2026-06
- 1.35LetPub ·
- SNIP 2026-06
- 1.02LetPub ·
- h-index
- 98LetPub ·
- h-index
- 168OpenAlex ·
- i10-index
- 9,796OpenAlex ·
- 2-year mean citedness
- 6.11OpenAlex ·
- Self-citation rate
- 3.6%LetPub ·
- Share of gold OA articles
- 22.16%LetPub ·
Volume
- Articles per year
- 1,798LetPub ·
Articles by year OpenAlex count · 16,710 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 1,232 | 284 | 659 |
| 2025 | 1,963 | 483 | 9,505 |
| 2024 | 2,291 | 613 | 23,330 |
| 2023 | 1,673 | 401 | 26,082 |
| 2022 | 1,054 | 242 | 23,389 |
| 2021 | 1,059 | 242 | 29,144 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
87 daysMedian, submission to acceptance · P25–P75 62 days – 124 days
- Acceptance to online
- median 5 days (175 articles)
- Submission to online
- median 93 days
- Sample
- 175 articles with submission and acceptance dates (4,234 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 2.7 monthsLetPub ·
- Average acceptance (community reports)
- 81.66%LetPub ·
- Submission to first decision
- 1 daysPublisher website ·
- First decision after review
- 39 daysPublisher website ·
- Submission to acceptance
- 97 daysPublisher website ·
- Acceptance to publication
- 8 daysPublisher website ·
- Peer review
- Single anonymous peer reviewPublisher website
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Hybrid open accessLetPub
A subscription journal in which authors can pay to publish their article open access.
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| OpenAlex | USD 3,220 / EUR 3,010 / GBP 2,580 / JPY 399,380 | — | — | |
| Publisher website | USD 3,500 | — | — |
A hybrid journal charges the APC only when the author chooses open access; publishing under the subscription model is usually free.
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
Open calls for papers1, by deadline
Publisher websiteWhat to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Manuscript length
- ≤ 3,000 words
- Reference style
- Numbered, in order of citation
- Highlights
- Required
- Not considered
- meta-analyses
Article types accepted11, with length limits
- commentarymission before submitting a manuscript. Commentaries (3000 words) will serve as the means for expressing controversial, critmain text ≤ 3,000 words
- editorial• Full-length articles are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manuscri…Length not stated
- full-length articlesFull-length articles are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manuscript…Length not stated
- invited commentaryInvited Commentary. Topical editorials, commentaries, prospective reviews and hypotheses demonstrating acceptable standards of originality.Length not stated
- original research• Full-length articles are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manuscri…Length not stated
- preliminary studies/reportsPreliminary Studies/Reports. This section is for the publication of new observations that are promising but have not achieved the stature of a regular article, …Length not stated
- regular article• Full-length articles are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manuscri…Length not stated
- review• Full-length articles are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manuscri…Length not stated
- reviewsReviews are comprehensive appraisals of research and clinical outcomes in a field of current interest. All reviews are subject to the normal review process.Length not stated
- short communication• Full-length articles are full-length descriptions of original research. The scope may include basic science, clinical results, or applications. These manuscri…Length not stated
- short communicationsShort Communications. These are short manuscripts that have important and generally conclusionary data on a specific issue. They should consist of no more than …Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- NETHERLANDS
- Language
- English
- Frequency
- Monthly
- Founded
- 2001
- ISSN
- 1567-5769
- Electronic ISSN
- 1878-1705
- Official links
- Journal homepage ↗LetPub
- Submission system ↗Publisher website
- Special issues ↗Publisher website
FAQ
Frequently asked questions about International Immunopharmacology
What CAS zone is International Immunopharmacology in?
In the 2025 upgraded edition of the CAS Journal Ranking, International Immunopharmacology is in Zone 2 of Medicine, and in Zone 2 of the minor category Pharmacology & Pharmacy / Immunology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of International Immunopharmacology?
The latest impact factor listed by LetPub is 5.61; CiteScore 8.1, h-index 168.
How long does peer review take at International Immunopharmacology?
Based on the dates recorded on 175 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 87 days (interquartile range 62–124 days); authors report an average review time of about 2.7 months; the community-reported acceptance is “about 81.66%”. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of International Immunopharmacology?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Manuscript length: ≤ 3,000 words; Reference style: Numbered, in order of citation; Highlights: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of International Immunopharmacology based?
Of the 87 board members whose country the journal's board page names, 48 (about 55%) are in mainland China; the countries named most often are Mainland China (48), United States (18) and India (6). Counted from the institutions listed on the board page; for reference only.
Which databases index International Immunopharmacology?
According to LetPub and DOAJ records, International Immunopharmacology is indexed in SCIE and Scopus.
Is International Immunopharmacology open access, and what is the APC?
International Immunopharmacology is a hybrid journal. For open-access publication: APC about USD 3,220.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-25). Last updated: .